Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | BCHE | P06276 | 13/20 | 0.52 |
| ▸ | ACHE | P22303 | 4/20 | 0.48 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9568253 | 0.80 | KMT2A (0.55) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL2175748 | 0.80 | — | — | |
| SCHEMBL1718054 | 0.72 | MAOA (0.64) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL6008164 | 0.69 | MEN1 (0.47) | MAOABCHEMEN1LMNAKMT2A | |
| SCHEMBL3235747 | 0.69 | MAOA (0.58) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL12655447 | 0.69 | MAOA (0.58) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL8038574 | 0.69 | MAOA (0.58) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL29377505 | 0.69 | MAOA (1.00) | MAOABCHENOX1MEN1LMNA | |
| SCHEMBL18932210 | 0.69 | MAOA (0.58) | MAOABCHEACHENOX1MEN1 | |
| SCHEMBL231247 | 0.69 | MAOA (1.00) | MAOABCHENOX1MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001092240-A1 | NOVEL N-SUBSTITUTED PHENOTHIAZINES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES | DALHOUSIE UNIVERSITY (CA) | 2001-12-06 | — | — | WO | claimed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2007-05-03 | — | — | US | disclosed |
| EP-1749001-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | Aventis Pharmaceuticals, Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005111025-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| WO-2004082826-A3 | CATALYST COMPOSITION AND METHOD FOR CHLORINATING AROMATIC COMPOUNDS | GEN ELECTRIC (US) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004082826-A2 | CATALYST COMPOSITION AND METHOD FOR CHLORINATING AROMATIC COMPOUNDS | GENERAL ELECTRIC COMPANY (US) | 2004-09-30 | — | — | WO | disclosed |
| WO-2001092240-A1 | NOVEL N-SUBSTITUTED PHENOTHIAZINES AND THEIR USE AS MODULATORS OF SERINE HYDROLASE ENZYMES | DALHOUSIE UNIVERSITY (CA) | 2001-12-06 | — | — | WO | disclosed |
| US-5767141-A | Substituted propane derivatives, a process for their preparation and the use of the compounds for treating diseases | HOECHST AKTIENGESELLSCHAFT (DE) | 1998-06-16 | — | — | US | disclosed |
| US-5463062-A | Inhibitors of glucose-6-phosphatase system | HOECHST AKTIENGESELLSCHAFT (DE) | 1995-10-31 | — | — | US | disclosed |
| US-4766125-A | N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia | JANSSEN PHARMACEUTICA N.V. (BE) | 1988-08-23 | — | — | US | disclosed |
| EP-0068544-A2 | Novel N-aryl-piperazinealkanamides | JANSSEN PHARMACEUTICA N.V. (BE) | 1983-01-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099955-A1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | DRD3, DRD2, DRD4 | MAOA 257/4885BCHE 1680/4885ACHE 476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.